-

Parnell Adds Sevoflurane to Its Growing Veterinary Anesthesia Portfolio

Parnell now offers a comprehensive anesthesia toolkit from a single, trusted partner

original Parnell Sevoflurane Inhalation Anesthetic

Parnell Sevoflurane Inhalation Anesthetic

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support veterinary teams across the full procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, the new offering provides clinics with a reliable, cost-effective inhalant anesthetic option from a company veterinary teams already rely on.

The addition reinforces Parnell’s commitment to delivering confidence at every stage of the anesthetic protocol. With Sevoflurane joining PropofolVet Multidose, Parnell Brand Dexmedetomidine Hydrochloride Injection, CONTRASED™ (atipamezole hydrochloride), and Isoflurane Inhalation Anesthetic, practices can now source a complete anesthesia toolkit from a single, accountable partner.

“Veterinary professionals place immense trust in the products they use during anesthesia, and that responsibility drives everything we do,” said Pablo Lamberto, DVM, U.S. General Manager at Parnell. “In a category where consistency and reliability matter as much as cost, the addition of Sevoflurane allows us to better support clinics with dependable, high-quality options across the entire anesthesia protocol.”

Key Features

  • Indicated for induction and maintenance of general anesthesia in dogs
  • Nonflammable and nonexplosive, supporting a safer clinical environment
  • Rapid induction and recovery profile consistent with Sevoflurane's established clinical performance
  • Available in 250 mL bottles
  • Competitively priced to support veterinary practices managing anesthesia costs without compromise

Supporting the Whole Team

Parnell's commitment to veterinary teams extends beyond the product. The Foundations of Anesthesia & Sedation Certificate Program — an online course offering 10 RACE-approved CE hours — is designed to build staff competency and confidence in anesthesia protocols. For practices investing in both clinical excellence and team development, the program complements the portfolio as part of a broader support ecosystem. Learn more at parnell.com/education.

For more information about Sevoflurane Inhalation Anesthetic, visit parnell.com/sevoflurane or contact your local distributor representative.

About Parnell

Parnell is a veterinary pharmaceutical company focused on developing, manufacturing, and commercializing animal health solutions across anesthesia and beyond. With a strong commitment to quality and customer partnerships, Parnell manufactures and markets products for companion and production animals in 10 countries. Learn more at www.parnell.com.

©2026 Parnell Technologies Pty LTD. CONTRASED is a trademark of Parnell Technologies Pty LTD. MKT-26-083 PC US

Contacts

Media Contact:
Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913‑274‑2100

Industry:

Parnell

Release Versions
English

Contacts

Media Contact:
Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913‑274‑2100

Social Media Profiles
Parnell on Facebook
Parnell on Instagram
Parnell on LinkedIn
More News From Parnell

Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities

SYDNEY, Australia--(BUSINESS WIRE)--Parnell today announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, according to the Securities Purchase Agreement dated November 26, 2025. With this strategic acquisition, Parnell strengthens its U.S. operations and further advances its long-term commitment to delivering high‑quality products, reliable supply, and an enhanced level of support to its customers and distribution partners. Noble Pharma significantly enhances Pa...

Parnell Launches nixiFLOR® - First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell Technologies Pty. Ltd. announced the U.S. launch of nixiFLOR® (florfenicol and flunixin meglumine) injectable solution, recently approved by the U.S. Food and Drug Administration for the treatment of bovine respiratory disease (BRD) and control of BRD-associated pyrexia (fever) in beef and non-lactating dairy cattle. nixiFLOR® is the first FDA-approved generic version of Resflor Gold®, containing the same active ingredients, florfenicol and flunixin...

Parnell Launches Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution for Dogs

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution, a Class III controlled veterinary product formulated for humane, painless, and rapid euthanasia of dogs, available in 100 mL multi‑dose vials. Designed for clinical reliability and ease of identification in practice settings, Parnell’s formulation contains 390 mg/mL pentobarbital sodium and 50 mg/mL phenytoin sodium, with Rhodamine B (bluish‑red dye) to clea...
Back to Newsroom